In Silico Modeling of a Mathematically Optimized Staggered Epigenetic Priming Regimen Range: Candidate 1 (WA / Quercetin / Silibinin Architecture)

Abstract & Prior Art Disclosure This dataset establishes public domain Prior Art for a mathematically optimized, multi-candidate in silico model designed to induce cellular chemosensitisation across a series of phytotherapeutic combinations. While isolated anti-neoplastic properties of compounds such as Withaferin A (WA), Quercetin, Silibinin, and EGCG are documented in baseline oncology literature, their simultaneous kinetic orchestration and staggered pre-conditioning timing remain unoptimized. This model introduces a computational blueprint utilizing Nelder-Mead optimization across 100,000 Monte Carlo validation draws to bracket peak synergistic tumor cell cytotoxicity while driving metabolic liability indices down. By introducing a precisely timed staggered priming window (T-48h to T-24h), a maintenance refresh (T-24h to T-12h), and a pre-infusion metabolic washout barrier (T-12h to T0), this framework maximizes chemosensitisation while bypassing direct Drug-Drug Interaction (DDI) liabilities. This complete dataset is donated openly to the cancer research community to serve as an unpatentable baseline for future in vitro and in vivo validation. Complete Optimized Candidates Hierarchy (Candidates 1–10) Candidate 1: WA / Quercetin / Silibinin [3in-1, Opt Cap, Priming -36h to -18h] Candidate 2: EGCG / WA / Silibinin [3in-1, Opt Cap, Priming -36h to -18h] Candidate 3: WA / Silibinin [2in-1, Opt Cap, Priming -36h to -18h] Candidate 4: EGCG / Quercetin / WA / Silibinin [4in-1, Opt Cap, Priming -36h to -18h] Candidate 5: WA / Silibinin [2in-1, Opt Cap, Priming -48h to -24h] Candidate 6: EGCG / Quercetin / WA / Silibinin [4in-1, Opt Cap, Priming -48h to -24h] Candidate 7: Quercetin / WA / Silibinin [3in-1, Opt Cap, Priming -48h to -24h] Candidate 8: EGCG / Quercetin / WA / Silibinin [4in-1, Opt Cap, Priming -36h to -48h] Candidate 9: EGCG / Quercetin / WA / Silibinin [4in-1, Opt Cap, Priming -18h to -36h] Candidate 10: Silibinin / Galangin / EGCG [3in-1, Opt Cap, Priming -36h to -18h] Defensive Anti-Bracketing & Broad Functional Declaration This disclosure covers and invalidates the novelty of the entire operational sequence and timing continuum across all listed candidates: 1. Initial Pre-Conditioning Priming Range: T-48h to T-24h 2. Kinetic Refresher Maintenance Range: T-24h to T-12h 3. Metabolic Washout Safety Window: T-12h to T0 This broad functional disclosure explicitly covers the application of this timing sequence to equivalent plant-derived HDAC inhibitors, apoptotic synergists, and chemoprotective buffers identified across the entire evaluated model parameter space, barring any commercial entity from claiming monopoly utility/method patent rights over any component or candidate variant of this timing framework.